Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
Browsing: Clinical Trial
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new…
The ASPECT-NP study, rationale, results and repercussions – an interview with Igancio Martin-Loeches and Marin Kollef
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
A large-scale trial of RTS,S – the world’s first malaria vaccine to provide partial protection – is due to commence in Malawi, Kenya and Ghana.
ECCMID19: Suvratoxumab completes Phase II for treatment of Staphylococcus aureus in the New Drugs 4 Bad Bugs program
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.